Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BG3B
|
|||
| Former ID |
DIB008930
|
|||
| Drug Name |
VX-135
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Vertex pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01726946) A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C. U.S. National Institutes of Health. | |||
| REF 2 | All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.